Blood and tissue neuroendocrine tumor gene cluster analysis correlate, define hallmarks and predict disease status

Endocrine-Related Cancer

Volumn 22, Issue 4, 2015, Pages 561-575

  Kidd, Mark ^a   Drozdov, Ignat ^a   Modlin, Irvin ^a  

^a Wren Laboratories   (United States)

Author keywords

Algorithm; Biomarker; Carcinoid; Gastroenteropancreatic; Hallmarks; Ki 67; Multigene transcript; NET; Neuroendocrine; PCR; Proliferation

Indexed keywords

TRANSCRIPTOME; TUMOR MARKER;

ADULT; AGED; APOPTOME; AREA UNDER THE CURVE; ARTICLE; BLOOD; BLOOD ANALYSIS; BLOOD SAMPLING; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE ACTIVITY; DNA INTEGRATION; EPIGENETICS; EPIGENOME; FEMALE; GENE CLUSTER; GENE EXPRESSION; GENE REGULATORY NETWORK; GENETIC ANALYSIS; GENETIC IDENTIFICATION; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MARKER GENE; METABOLOME; MICROARRAY ANALYSIS; NEUROENDOCRINE TUMOR; OUTCOME ASSESSMENT; PLUROME; PRINCIPAL COMPONENT ANALYSIS; PROLIFEROME; PROSPECTIVE STUDY; REAL TIME POLYMERASE CHAIN REACTION; RECEIVER OPERATING CHARACTERISTIC; SECRETOME; SIGNALOME; SSTROME; TISSUE LEVEL; ADOLESCENT; ALGORITHM; CLUSTER ANALYSIS; DISEASE COURSE; GENETICS; MIDDLE AGED; MULTIGENE FAMILY; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; BIOMARKERS, TUMOR; CLUSTER ANALYSIS; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIGENE FAMILY; NEUROENDOCRINE TUMORS; TRANSCRIPTOME; YOUNG ADULT;

EID: 84940109492     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-15-0092     Document Type: Article

References (61)

1. Banck MS, Kanwar R, Kulkarni AA, Boora GK, Metge F, Kipp BR, Zhang L, Thorland EC, Minn KT, Tentu R et al. 2013 The genomic landscape of small intestine neuroendocrine tumors. Journal of Clinical Investigation 123 2502-2508. (doi:10.1172/JCI67963)
2. Boulesteix AL & Slawski M 2009 Stability and aggregation of ranked gene lists. Briefings in Bioinformatics 10 556-568. (doi:10.1093/bib/bbp034)
3. Bralten LB, Kloosterhof NK, Gravendeel LA, Sacchetti A, Duijm EJ, Kros JM, van den Bent MJ, Hoogenraad CC, Sillevis Smitt PA & French PJ 2010 Integrated genomic profiling identifies candidate genes implicated in glioma-genesis and a novel LEO1-SLC12A1 fusion gene. Genes, Chromosomes & Cancer 49 509-517. (doi:10.1002/gcc.20760)
4. Burock S, Herrmann P, Wendler I, Niederstrasser M, Wernecke KD & Stein U 2015 Circulating metastasis associated in colon cancer 1 transcripts in gastric cancer patient plasma as diagnostic and prognostic biomarker. World Journal of Gastroenterology 21 333-341. (doi:10.3748/wjg.v21.i1.333)
5. Cao Y, Gao Z, Li L, Jiang X, Shan A, Cai J, Peng Y, Li Y, Jiang X, Huang X et al. 2013 Whole exome sequencing of insulinoma reveals recurrent T372R mutations in YY1. Nature Communications 4 2810. (doi:10.1038/ncomms3810)
6. Cui T, Hurtig M, Elgue G, Li SC, Veronesi G, Essaghir A, Demoulin JB, Pelosi G, Alimohammadi M, Oberg K et al. 2010 Paraneoplastic antigen Ma2 autoantibodies as specific blood biomarkers for detection of early recurrence of small intestine neuroendocrine tumors. PLoS ONE 5 e16010. (doi:10.1371/journal.pone.0016010)
7. Danila DC, Anand A, Schultz N, Heller G, Wan M, Sung CC, Dai C, Khanin R, Fleisher M, Lilja H et al. 2014 Analytic and clinical validation of a prostate cancer-enhanced messenger RNA detection assay in whole blood as a prognostic biomarker for survival. European Urology 65 1191-1197. (doi:10.1016/j.eururo.2013.07.006)
8. Drozdov I, Kidd M, Nadler B, Camp RL, Mane SM, Hauso O, Gustafsson BI& Modlin IM 2009 Predicting neuroendocrine tumor (carcinoid) neoplasia using gene expression profiling and supervised machine learning. Cancer 115 1638-1650. (doi:10.1002/cncr.24180)
9. Engels CC, Ruberta F, de Kruijf EM, van Pelt GW, Smit VT, Liefers GJ, Matsushima T, Shibayama M, Ishihara H, van de Velde CJ et al. 2013 The prognostic value of apoptotic and proliferative markers in breast cancer. Breast Cancer Research and Treatment 142 323-339. (doi:10.1007/s10549-013-2748-y)
10. Fleige S, Walf V, Huch S, Prgomet C, Sehm J & Pfaffl MW 2006 Comparison of relative mRNA quantification models and the impact of RNA integrity in quantitative real-time RT-PCR. Biotechnology Letters 28 1610-1613. (doi:10.1007/s10529-006-9127-2)
11. Franceschini A, Szklarczyk D, Frankild S, Kuhn M, Simonovic M, Roth A, Lin J, Minguez P, Bork P, vonMering C et al. 2013 STRINGv9.1: protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Research 41 D808-D815. (doi:10.1093/nar/gks1094)
12. Francis JM, Kiezun A, Ramos AH, Serra S, Pedamallu CS, Qian ZR, Banck MS, Kanwar R, Kulkarni AA, Karpathakis A et al. 2013 Somatic mutation of CDKN1B in small intestine neuroendocrine tumors. Nature Genetics 45 1483-1486. (doi:10.1038/ng.2821)
13. Gracz AD & Magness ST 2014 Defining hierarchies of stemness in the intestine: evidence from biomarkers and regulatory pathways. American Journal of Physiology. Gastrointestinal and Liver Physiology 307 G260-G273. (doi:10.1152/ajpgi.00066.2014)
14. Grimm M, Schmitt S, Teriete P, Biegner T, Stenzl A, Hennenlotter J, Muhs HJ, Munz A, Nadtotschi T, Konig K et al. 2013 A biomarker based detection and characterization of carcinomas exploiting two fundamental biophysical mechanisms in mammalian cells. BMC Cancer 13 569. (doi:10.1186/1471-2407-13-569)
15. Hanahan D & Weinberg RA 2000 The hallmarks of cancer. Cell 100 57-70. (doi:10.1016/S0092-8674(00)81683-9)
16. Hanahan D & Weinberg RA 2011 Hallmarks of cancer: the next generation. Cell 144 646-674. (doi:10.1016/j.cell.2011.02.013)
17. Hanley JA & McNeil BJ 1982 The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143 29-36. (doi:10.1148/radiology.143.1.7063747)
18. Hanley JA & McNeil BJ 1983 A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 148 839-843. (doi:10.1148/radiology.148.3.6878708)
19. Hogarty MD, Norris MD, Davis K, Liu X, Evageliou NF, Hayes CS, Pawel B, Guo R, Zhao H, Sekyere E et al. 2008 ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma. Cancer Research 68 9735-9745. (doi:10.1158/0008-5472.CAN-07-6866)
20. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B & Speed TP 2003 Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Research 31 e15. (doi:10.1093/nar/gng015)
21. Jaeger U & Kainz B 2003 Monitoring minimal residual disease in AML: the right time for real time. Annals of Hematology 82 139-147. (doi:10.1007/s00277-002-0601-1)
22. Kadara H, Behrens C, Yuan P, Solis L, Liu D, Gu X, Minna JD, Lee JJ, Kim E, Hong WK et al. 2011 A five-gene and corresponding protein signature for stage-I lung adenocarcinoma prognosis. Clinical Cancer Research 17 1490-1501. (doi:10.1158/1078-0432.CCR-10-2703)
23. Karhoff D, Sauer S, Schrader J, Arnold R, Fendrich V, Bartsch DK & Horsch D 2007 Rap1/B-Raf signaling is activated in neuroendocrine tumors of the digestive tract and Raf kinase inhibition constitutes a putative therapeutic target. Neuroendocrinology 85 45-53. (doi:10.1159/000100508)
24. Kauffmann A, Gentleman R & Huber W 2009 arrayQualityMetrics - a bioconductor package for quality assessment of microarray data. Bioinformatics 25 415-416. (doi:10.1093/bioinformatics/btn647)
25. Kidd M, Eick G, Shapiro MD, Camp RL, Mane SM & Modlin IM 2005 Microsatellite instability and gene mutations in transforming growth factor-b type II receptor are absent in small bowel carcinoid tumors. Cancer 103 229-236. (doi:10.1002/cncr.20750)
26. Kidd M, Modlin IM, Mane SM, Camp RL, Eick G & Latich I 2006 The role of genetic markers - NAP1L1, MAGE-D2, and MTA1 - in defining smallintestinal carcinoid neoplasia. Annals of Surgical Oncology 13 253-262. (doi:10.1245/ASO.2006.12.011)
27. Kidd M, Nadler B, Mane S, Eick G, Malfertheiner M, Champaneria M, Pfragner R & Modlin I 2007 GeneChip, geNorm, and gastrointestinal tumors: novel reference genes for real-time PCR. Physiological Genomics 30 363-370. (doi:10.1152/physiolgenomics.00251.2006)
28. Kidd M, Modlin IM & Drozdov I 2014 Gene network-based analysis identifies two potential subtypes of small intestinal neuroendocrine tumors. BMC Genomics 15 595. (doi:10.1186/1471-2164-15-595)
29. Kim M, Jang HR, Kim JH, Noh SM, Song KS, Cho JS, Jeong HY, Norman JC, Caswell PT, Kang GH et al. 2008 Epigenetic inactivation of protein kinase D1 in gastric cancer and its role in gastric cancer cell migration and invasion. Carcinogenesis 29 629-637. (doi:10.1093/carcin/bgm291)
30. Kim HS, Lee HS, Nam KH, Choi J& KimWH 2014 p27 loss is associated with poor prognosis in gastroenteropancreatic neuroendocrine tumors. Cancer Research and Treatment 46 383-392. (doi:10.4143/crt.2013.102)
31. Lawrence B, Gustafsson BI, Kidd M, Pavel M, Svejda B&Modlin IM 2011 The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors. Endocrinology and Metabolism Clinics of North America 40111-134, viii. (doi:10.1016/j.ecl.2010.12.001)
32. Leja J, Essaghir A, Essand M, Wester K, Oberg K, Totterman TH, Lloyd R, Vasmatzis G, Demoulin JB & Giandomenico V 2009 Novel markers for enterochromaffin cells and gastrointestinal neuroendocrine carcinomas. Modern Pathology 22 261-272. (doi:10.1038/modpathol.2008.174)
33. Leotlela PD, Jauch A, Holtgreve-Grez H & Thakker RV 2003 Genetics of neuroendocrine and carcinoid tumours. Endocrine-Related Cancer 10 437-450. (doi:10.1677/erc.0.0100437)
34. Maglott D, Ostell J, Pruitt KD & Tatusova T 2011 Entrez Gene: gene-centered information at NCBI. Nucleic Acids Research 39 D52-D57. (doi:10.1093/nar/gkq1237)
35. Marinoni I, Kurrer AS, Vassella E, Dettmer M, Rudolph T, Banz V, Hunger F, Pasquinelli S, Speel EJ & Perren A 2014 Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors. Gastroenterology 146 453-460 (e455). (doi:10.1053/j.gastro.2013.10.020)
36. Marotta V, Nuzzo V, Ferrara T, Zuccoli A, Masone M, Nocerino L, Del Prete M, Marciello F, Ramundo V, Lombardi G et al. 2012 Limitations of chromogranin A in clinical practice. Biomarkers 17 186-191. (doi:10.3109/1354750X.2012.654511)
37. McClintick JN & Edenberg HJ 2006 Effects of filtering by present call on analysis of microarray experiments. BMC Bioinformatics 7 49. (doi:10.1186/1471-2105-7-49)
38. Miretti S, Roato I, Taulli R, Ponzetto C, Cilli M, Olivero M, DiRenzo MF, Godio L, Albini A, Buracco P et al. 2008 A mouse model of pulmonarymetastasis from spontaneous osteosarcomamonitored in vivo by luciferase imaging. PLoS ONE 3 e1828. (doi:10.1371/journal.pone.0001828)
39. Modlin I, Drozdov I&Kidd M 2013a The Identification of gutneuroendocrine tumor disease by multiple synchronous transcript analysis in blood. PLoS ONE 8 e63364. (doi:10.1371/journal.pone.0063364)
40. Modlin I, Drozdov I & Kidd M 2013b A multitranscript blood neuroendocrine tumor molecular signature to identify treatment efficacy and disease progress. Journal of Clinical Oncology 31 (Suppl) A4137.
41. Modlin I, Drozdov I, Alaimo D, Callahan S, Teixeira N, Bodei L & Kidd M 2014a A multianalyte PCR blood test outperforms single analyte ELISAs for neuroendocrine tumor detection. Endocrine-Related Cancer 21 615-628. (doi:10.1530/ERC-14-0190)
42. Modlin I, Kidd M, Taylor A, Drozdov I & Bodei L 2014b Neuroendocrine tumor biomarkers: current status and perspectives. Neuroendocrinology 100 265-277. (doi:10.1159/000368363)
43. Modlin I, Drozdov I & Kidd M 2014c Gut neuroendocrine tumor blood qPCR fingerprint assay: characteristics and reproducibility. Clinical Chemistry 52 419-429. (doi:10.1515/cclm-2013-0496)
44. Modlin IM, Aslanian H, Bodei L, Drozdov I&KiddM2014d A PCR blood test outperforms chromograninAin carcinoid detectionand is unaffected by PPIs. Endocrine Connections 3 215-223. (doi:10.1530/EC-14-0100)
45. Muscarella LA, D'Alessandro V, la Torre A, Copetti M, De Cata A, Parrella P, Sperandeo M, Pellegrini F, Frusciante V, Maiello E et al. 2011 Gene expression of somatostatin receptor subtypes SSTR2a, SSTR3 and SSTR5 in peripheral blood of neuroendocrine lung cancer affected patients. Cellular Oncology 19 19. (doi:10.1007/s13402-011-0025-9)
46. Naik S, Dothager RS, Marasa J, Lewis CL & Piwnica-Worms D 2009 Vascular endothelial growth factor receptor-1 is synthetic lethal to aberrant β-catenin activation in colon cancer. Clinical Cancer Research 15 7529-7537. (doi:10.1158/1078-0432.CCR-09-0336)
47. Oehler VG & Radich JP 2006Monitoring BCR-ABL in the treatment of chronic myeloid leukemia by polymerase chain reaction. Current Hematologic Malignancy Reports 1 152-159. (doi:10.1007/s11899-996-0003-x)
48. Ostergaard M, Olesen LH, Hasle H, Kjeldsen E & Hokland P 2004 WT1 gene expression: an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients - results from a singlecentre study. British Journal of Haematology 125 590-600. (doi:10.1111/j.1365-2141.2004.04952.x)
49. Perren A, Schmid S, Locher T, Saremaslani P, Bonvin C, Heitz PU & Komminoth P 2004 BRAF and endocrine tumors: mutations are frequent in papillary thyroid carcinomas, rare in endocrine tumors of the gastrointestinal tract and not detected in other endocrine tumors. Endocrine-Related Cancer 11 855-860. (doi:10.1677/erc.1.00841)
50. Raza A, Ali Z, Irfan J, Murtaza S & Shakeel S 2012 Analytical variables influencing the HCV RNA determination by TaqMan real-time PCR in routine clinical laboratory practice. Molecular Biology Reports 39 7421-7427. (doi:10.1007/s11033-012-1574-3)
51. Reubi JC, Waser B, Schaer JC & Laissue JA 2001 Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. European Journal of Nuclear Medicine 28 836-846. (doi:10.1007/s002590100541)
52. Rindi G & Wiedenmann B 2011 Neuroendocrine neoplasms of the gut and pancreas: new insights. Nature Reviews. Endocrinology 2 120. (doi:10.1038/nrendo.2011.120)
53. Rindi G, Kloppel G, Alhman H, Caplin M, Couvelard A, de Herder WW, Erikssson B, Falchetti A, Falconi M, Komminoth P et al. 2006 TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Archiv 449 395-401.
54. Rindi G, Kloppel G, Couvelard A, Komminoth P, Korner M, Lopes JM, McNicol AM, Nilsson O, Perren A, Scarpa A et al. 2007 TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Archiv 451 757-762.
55. Schimmack S, Taylor A, Lawrence B, Alaimo D, Schmitz-Winnenthal H, Buchler MW, Modlin IM & Kidd MA 2014 A mechanistic role for the chromatin modulator, NAP1L1, in pancreatic neuroendocrine neoplasm proliferation and metastases. Epigenetics & Chromatin 7 15. (doi:10.1186/1756-8935-7-15)
56. Tannapfel A, Vomschloss S, Karhoff D, Markwarth A, Hengge UR, Wittekind C, Arnold R & Horsch D 2005 BRAF gene mutations are rare events in gastroenteropancreatic neuroendocrine tumors. American Journal of Clinical Pathology 123 256-260. (doi:10.1309/YQBR9C05RU4DD3RN)
57. Travis WD, Brambilla E, Muller-Hermlink H & Harris C 2004 World Health Organization classification of tumours. Pathology and genetics of tumours of the lung, pleura, thymus and heart. Lyon, France: IARC Press.
58. Walenkamp A, Crespo G, Fierro Maya F, Fossmark R, Igaz P, Rinke A, Tamagno G, Vitale G, Oberg K & Meyer T 2014 Hallmarks of gastrointestinal neuroendocrine tumours: implications for treatment. Endocrine-Related Cancer 21 R445-R460. (doi:10.1530/ERC-14-0106)
59. Wang E, Zaman N, McGee S, Milanese JS, Masoudi-Nejad A & O'Connor- McCourt M 2014 Predictive genomics: a cancer hallmark network framework for predicting tumor clinical phenotypes using genome sequencing data. Seminars in Cancer Biology 30 4-12. (doi:10.1016/j.semcancer.2014.04.002)
60. Wulbrand U, Wied M, Zofel P, Goke B, Arnold R & Fehmann H 1998 Growth factor receptor expression in human gastroenteropancreatic neuroendocrine tumours. European Journal of Clinical Investigation 28 1038-1049. (doi:10.1046/j.1365-2362.1998.00397.x)
61. Zhang L, Cao Z, RuanM, Zeng Q, Zhao L, Li Q, Zou Y, Wang J & Zhu X 2014 Monitoring the AML1/ETO fusion transcript to predict outcome in childhood acute myeloid leukemia. Pediatric Blood & Cancer 61 1761-1766. (doi:10.1002/pbc.25109)